Early evidence has confirmed that gliomas with IDH mutation and 1p/19q codeletion have better survival, whereas glioblastoma with telomerase reverse transcriptase (TERT) promoter mutation have worse survival6. This evidence concerns the gene TERT and central nervous system cancer.